OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Roué on Interest With TG-1701 in Ibrutinib-Resistant MCL Models

July 9th 2020

Gaël Roué, PhD, discusses interest regarding the novel irreversible inhibitor TG-1701 in models of ibrutinib (Imbruvica)-resistant mantle cell lymphoma.

Dr. Leslie on the Benefits With Zanubrutinib in MCL

July 9th 2020

Lori A. Leslie, MD, discusses the benefits with zanubrutinib (Brukinsa) in the treatment of patients with mantle cell lymphoma.

Dr. Weisel on Interim Analysis With Isatuximab Plus KRd in High-Risk Myeloma

July 9th 2020

Katja Weisel, MD, discusses the interim analysis of the phase 2 GMMG-Concept trial with isatuximab-irfc in combination with carfilzomib, lenalidomide, and dexamethasone in high-risk patients with newly diagnosed multiple myeloma.

Dr. Katz on Redefining Risk Stratification in Prostate Cancer

July 9th 2020

Aaron E. Katz, MD, FACS, discusses redefining risk stratification for men with prostate cancer.

Dr. Davids on Updated Data With Ibrutinib/Umbralisib in R/R CLL and MCL

July 8th 2020

Matthew S. Davids, MD, MMSc, discusses updated findings from a phase 1/1b study which examined the combination of ibrutinib (Imbruvica) and umbralisib in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple Myeloma

July 8th 2020

Jesus G. Berdeja, MD, discusses the dosing of the investigational CAR T-cell product JNJ-4528 in patients with relapsed/refractory multiple myeloma.

Dr. Shore on Benefits of Immunotherapy INO-5150 in Recurrent Prostate Cancer

July 8th 2020

Neal D. Shore, MD, FACS, discusses the potential benefits of the immunotherapy INO-5150 for patients with biochemically recurrent prostate cancer.

Dr. Bekaii-Saab on Second-Line Treatment Options in HCC

July 8th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses second-line treatment options in hepatocellular carcinoma.

Dr. Jonasch on the Safety Profile of MK-6482 in Von Hippel-Lindau Disease–Associated RCC

July 8th 2020

Eric Jonasch, MD, discusses the safety profile of the investigational oral hypoxia-inducible factor-2α inhibitor MK-6482 in Von Hippel-Lindau disease–associated renal cell carcinoma.

Dr. Kopetz on the Rationale for the BEACON CRC Study in BRAF V600E-Mutant mCRC

July 8th 2020

Scott Kopetz, MD, PhD, FACP, discusses the rationale for the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.

Dr. Talati on Rationale for Collecting Real-World Data on Venetoclax/HMA Combos in AML

July 8th 2020

Chetasi Talati, MD, discusses the design of a chart review study with venetoclax and hypomethylating agents in older patients with newly-diagnosed acute myeloid leukemia.

Dr. Hope on the Effectiveness of 68Ga-PSMA-11 PET in Prostate Cancer

July 8th 2020

Thomas A. Hope, MD, discusses the positive findings from a phase 3 imaging study, which utilized 68Ga-PSMA-11 PET in the detection of pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Dr. Shore on the Potential Utility of Relugolix in Advanced Prostate Cancer

July 8th 2020

Neal D. Shore, discusses the potential utility of relugolix in patients with advanced prostate cancer.

Dr. Salani on the Current State of Biomarker Testing in Cervical Cancer

July 8th 2020

Ritu Salani, MD, MBA, discusses the current state of biomarker testing in cervical cancer.

Dr. Blank on Adjuvant Versus Neoadjuvant Approaches in Stage III Melanoma

July 8th 2020

Christian U. Blank, MD, PhD, discusses adjuvant versus neoadjuvant approaches in macroscopic stage III melanoma.

Dr. Gupta on Challenges With Perioperative Immunotherapy in Bladder Cancers

July 8th 2020

Shilpa Gupta, MD, discusses challenges with perioperative immunotherapy in bladder cancer.

Dr. Litton on the EMBRACA Trial in Advanced BRCA1/2+ Breast Cancer

July 8th 2020

Jennifer K. Litton, MD, discusses the phase 3 EMBRACA trial in patients with germline BRCA1/2-mutated metastatic HER2-negative breast cancer.

Dr. Neelapu on Potential Advantages of Allogeneic CAR T-Cell Therapy in Lymphoma

July 7th 2020

Sattva Neelapu, MD, discusses the potential advantages of allogeneic CAR T-cell therapy compared with autologous CAR T-cell therapy in lymphoma.

Dr. Hoffman on Advantages of Self-Administration With PTG-300 in Polycythemia Vera

July 7th 2020

Ronald Hoffman, MD, discusses the advantages of self-administration with the investigational hepcidin mimetic PTG-300 for patients with polycythemia vera (PV).

Dr. Ruan on Unanswered Questions Regarding Treatment Decisions in MCL

July 7th 2020

Jia Ruan, MD, PhD, discusses some of the unanswered questions regarding optimizing treatment selection in patients with mantle cell lymphoma.